Product Images Oxybutynin Chloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Oxybutynin Chloride NDC 82868-047 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 82868 047 30 Rev A 02 24
This is a description of Oxybutynin Chloride tablets. Each tablet contains 8 mg of Oxybutynin Chloride. The tablets come in a package of 30 tablets and are intended for prescription use only. The tablets should be stored at room temperature and kept out of reach of children. They have been repackaged from a specific product number by Northwind Pharmaceuticals in Indianapolis, IN. The expiration date listed is "000010000" with Lot number "0000000000".*
Structural Formula - figure 1 structure
Table 1 - figure 2 table1
This -generated text includes information about the parameters G, Toa, AUC, and UGy for two different units - R-Oybutynin and S-Ouybutynin. The values provided are for G (ng/ml), Toa (1), AUC (ng=h/mL), and UGy (ng=ml). The data shows numerical values and their respective units for each parameter, allowing for a comparison between R-Oybutynin and S-Ouybutynin.*
Figure 1 - figure 3 figure1
Table 2 - figure 4 table2
This text appears to show data related to different compounds and their concentrations. It includes measurements for R-Oxybutynin, S-Oxybutynin, R-Desethyloxybutynin, and S-Desethyloxybutynin in units of g/mL. Additionally, there are values listed under 'Toa' and 'AUC (ng*min/mL)' for each compound. The text mentions reflected data and the abbreviation "Cgfo," implying some form of analysis or comparison.*
Figure 2 - figure 5 figure2
Table 3 - figure 6 table3
This text provides a list of potential adverse events associated with the drug Oxybutynin Chioride. Some of the reported adverse events include urinary tract infection, insomnia, dizziness, blurred vision, dry mouth, constipation, and urinary retention. The percentages indicate the frequency of these events among users.*
KVK logo - figure 7 company logo
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
